Literature DB >> 22388644

Immunogenicity of biological therapeutics: from assay to patient.

Charlotte Krieckaert1, Theo Rispens, Gertjan Wolbink.   

Abstract

PURPOSE OF REVIEW: To give an overview of the current knowledge on assay techniques and clinical implications of immunogenicity of biological therapeutics. RECENT
FINDINGS: Assay techniques for the measurement of immunogenicity have improved, expanding the understanding of the immune response against biological therapeutics. Knowledge on the clinical effect of immunogenicity enables the treatment of patients in a targeted fashion, as a step towards personalized medicine.
SUMMARY: Biological medications are able to induce an antidrug immune response. Immunogenicity impairs clinical response and is associated with adverse events. Several confounding factors influence the measurement of immunogenicity, including drug interference and background problems. Concomitant administration of methotrexate lowers the frequency and amount of antibodies formed, whereby the efficacy of biologicals is improved. Algorithms for therapeutic drug monitoring could aid in adapting treatment strategies in a controlled setting.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22388644     DOI: 10.1097/BOR.0b013e3283521c4e

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  28 in total

Review 1.  Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review.

Authors:  Antoine Petitcollin; Amina Bensalem; Marie-Clémence Verdier; Camille Tron; Florian Lemaitre; Gilles Paintaud; Eric Bellissant; David Ternant
Journal:  Clin Pharmacokinet       Date:  2020-01       Impact factor: 6.447

2.  Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases.

Authors:  C C Mok; D van der Kleij; G J Wolbink
Journal:  Clin Rheumatol       Date:  2013-07-26       Impact factor: 2.980

3.  Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases.

Authors:  Eva L Kneepkens; Mieke F Pouw; Gerrit Jan Wolbink; Tiny Schaap; Michael T Nurmohamed; Annick de Vries; Theo Rispens; Karien Bloem
Journal:  Br J Clin Pharmacol       Date:  2017-08-22       Impact factor: 4.335

4.  Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.

Authors:  Roberto A Maldonado; Robert A LaMothe; Joseph D Ferrari; Ai-Hong Zhang; Robert J Rossi; Pallavi N Kolte; Aaron P Griset; Conlin O'Neil; David H Altreuter; Erica Browning; Lloyd Johnston; Omid C Farokhzad; Robert Langer; David W Scott; Ulrich H von Andrian; Takashi Kei Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

Review 5.  Anti-TNF in rheumatoid arthritis: an overview.

Authors:  Helga Radner; Daniel Aletaha
Journal:  Wien Med Wochenschr       Date:  2015-02-05

6.  Pre-Clinical In-Vitro Studies on Parameters Governing Immune Complex Formation.

Authors:  Marie Fichter; Gesa Richter; Alexander Bepperling; Paul Wassmann
Journal:  Pharmaceutics       Date:  2022-06-13       Impact factor: 6.525

Review 7.  Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis.

Authors:  Pauline A van Schouwenburg; Theo Rispens; Gerrit Jan Wolbink
Journal:  Nat Rev Rheumatol       Date:  2013-02-12       Impact factor: 20.543

Review 8.  Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.

Authors:  Joachim R Kalden; Hendrik Schulze-Koops
Journal:  Nat Rev Rheumatol       Date:  2017-11-21       Impact factor: 20.543

Review 9.  Pre-existing Antibody: Biotherapeutic Modality-Based Review.

Authors:  Boris Gorovits; Adrienne Clements-Egan; Mary Birchler; Meina Liang; Heather Myler; Kun Peng; Shobha Purushothama; Manoj Rajadhyaksha; Laura Salazar-Fontana; Crystal Sung; Li Xue
Journal:  AAPS J       Date:  2016-01-28       Impact factor: 4.009

10.  Value of drug level testing and antibody assays in optimising biological therapy.

Authors:  Séverine Vermeire; Ann Gils
Journal:  Frontline Gastroenterol       Date:  2012-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.